The prognostic and therapeutic implications of circulating tumor cell phenotype detection based on epithelial–mesenchymal transition markers in the first-line chemotherapy of HER2-negative metastatic breast cancer

Table 3 Multivariate analysis of clinicopathological characteristics and the combined criteria for predicting PFS

Variate	P	HR	95% CI
HR status	0.253	0.619	0.272–1.408
Previous endocrinotherapy	0.815	0.925	0.479–1.785
Position of metastatic site	0.172	0.654	0.356–1.203
Number of metastases	0.249	0.473	0.133–1.689
CA153	0.675	0.863	0.433–1.720
CEA	0.253	1.452	0.765–2.756
Combined criteria	0.003	2.688	1.407–5.134

PFS progression-free survival, HR hormone receptor, CA153 carbohydrate antigen 153, CEA carcinoembryonic antigen, HR hazard ratio, CI confidence interval

ISSN: 2523-3548